BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 24145525)

  • 1. Ganciclovir-resistant cytomegalovirus infections among lung transplant recipients are associated with poor outcomes despite treatment with foscarnet-containing regimens.
    Minces LR; Nguyen MH; Mitsani D; Shields RK; Kwak EJ; Silveira FP; Abdel-Massih R; Pilewski JM; Crespo MM; Bermudez C; Bhama JK; Toyoda Y; Clancy CJ
    Antimicrob Agents Chemother; 2014; 58(1):128-35. PubMed ID: 24145525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
    Reddy AJ; Zaas AK; Hanson KE; Palmer SM
    J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
    Myhre HA; Haug Dorenberg D; Kristiansen KI; Rollag H; Leivestad T; Asberg A; Hartmann A
    Transplantation; 2011 Jul; 92(2):217-23. PubMed ID: 21685829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection.
    Avery RK; Arav-Boger R; Marr KA; Kraus E; Shoham S; Lees L; Trollinger B; Shah P; Ambinder R; Neofytos D; Ostrander D; Forman M; Valsamakis A
    Transplantation; 2016 Oct; 100(10):e74-80. PubMed ID: 27495775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients: a single-center retrospective cohort study.
    Young PG; Rubin J; Angarone M; Flaherty J; Penugonda S; Stosor V; Ison MG
    Transpl Infect Dis; 2016 Jun; 18(3):390-5. PubMed ID: 27037651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection.
    Cherrier L; Nasar A; Goodlet KJ; Nailor MD; Tokman S; Chou S
    Am J Transplant; 2018 Dec; 18(12):3060-3064. PubMed ID: 30286286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus Immunoglobulin for Prophylaxis and Treatment of Cytomegalovirus Infection in the (Val)Ganciclovir Era: A Single-Center Experience.
    Lopez Garcia-Gallo C; García Fadul C; Laporta R; Portero F; Millan I; Ussetti P
    Ann Transplant; 2015 Nov; 20():661-6. PubMed ID: 26537426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganciclovir-resistant post-transplant cytomegalovirus infection due to combined deletion mutation at codons 595-596 of the UL97 gene.
    Leung PYM; Tran T; Testro A; Paizis K; Kwong J; Whitlam JB
    Transpl Infect Dis; 2019 Dec; 21(6):e13168. PubMed ID: 31498954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
    Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
    Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiology and Outcome of Ganciclovir-Resistant Cytomegalovirus Infection After Solid Organ Transplantation: A Single Transplant Center Experience in Thailand.
    Bruminhent J; Rotjanapan P; Watcharananan SP
    Transplant Proc; 2017 Jun; 49(5):1048-1052. PubMed ID: 28583524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients.
    Rho E; Näf B; Müller TF; Wüthrich RP; Schachter T; von Moos S
    Clin Transplant; 2021 Nov; 35(11):e14401. PubMed ID: 34181768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis.
    Mitsani D; Nguyen MH; Kwak EJ; Silveira FP; Vadnerkar A; Pilewski J; Crespo M; Toyoda Y; Bermudez C; Clancy CJ
    J Heart Lung Transplant; 2010 Sep; 29(9):1014-20. PubMed ID: 20598582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.
    Chen F; Bando T; Hanaoka N; Fukuse T; Hasegawa S; Wada H
    Jpn J Thorac Cardiovasc Surg; 2005 Oct; 53(10):562-4. PubMed ID: 16279588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ganciclovir-Resistant Cytomegalovirus Infection in Abdominal Solid Organ Transplant Recipients: Case Series and Review of the Literature.
    Rolling KE; Jorgenson MR; Descourouez JL; Mandelbrot DA; Redfield RR; Smith JA
    Pharmacotherapy; 2017 Oct; 37(10):1258-1271. PubMed ID: 28699311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient.
    Julin JE; van Burik JH; Krivit W; Webb C; Holman CJ; Clark HB; Balfour HH
    Transpl Infect Dis; 2002 Dec; 4(4):201-6. PubMed ID: 12535263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes.
    Eid AJ; Arthurs SK; Deziel PJ; Wilhelm MP; Razonable RR
    Clin Transplant; 2008; 22(2):162-70. PubMed ID: 18339135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of foscarnet for the management of ganciclovir-resistant or refractory cytomegalovirus infections: A single-center study.
    Pierce B; Richardson CL; Lacloche L; Allen A; Ison MG
    Transpl Infect Dis; 2018 Apr; 20(2):e12852. PubMed ID: 29380479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: comparison of treatment failure and antiviral resistance.
    van der Beek MT; Berger SP; Vossen AC; van der Blij-de Brouwer CS; Press RR; de Fijter JW; Claas EC; Kroes AC
    Transplantation; 2010 Feb; 89(3):320-6. PubMed ID: 20145523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to combined ganciclovir and foscarnet therapy in a liver transplant recipient with possible dual-strain cytomegalovirus coinfection.
    Rodriguez J; Casper K; Smallwood G; Stieber A; Fasola C; Lehneman J; Heffron T
    Liver Transpl; 2007 Oct; 13(10):1396-400. PubMed ID: 17902124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.